We are developing our technology in areas of high unmet medical need in (i) debilitating diseases; (ii) where chronic treatment is required to control disease; (iii) and where localised, non-systemic activity promises to improve safety and tolerability. The company also has a wide range of pioneering molecules as potential candidates for a range of gastrointestinal (GI) and ocular inflammatory conditions.

TopiVert’s most advanced drug candidates are:

  • Topical TOP1630 in the treatment of dry eye disease, which recently demonstrated proof of concept in a Phase 1/2a study in the US. 
  • Oral TOP1890 for the treatment of ulcerative colitis (UC) is set to enter a Phase 1 study in 2019.